Genezen
Indianapolis, IN · Lexington, MA
Compare AAV CDMOs in Asia
Compare AAV CDMOs in India
Compare Lentiviral CDMOs in Asia
Compare Lentiviral CDMOs in India
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
78.1
Signal Score
✓ FDA Inspections (1)
○ Clinical Trials
○ SEC Filings
✓ Press (6)
○ EMA GMP
○ MHRA GMP
✓ HC GMP (1)
Quick Facts: Genezen
- Signal Score
- 78.1/100 (as of 2026-10-29)
- Quality Compliance
- 100.0/100
- Headquarters
- Indianapolis, IN · Lexington, MA
- Modalities
- AAV, Lentiviral
- Active Programs
- No ClinicalTrials.gov matches confirmed — 2 partnership signals in press (announcements, not verified)
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Genezen
Mid-tier AAV/lentiviral specialist.
Signal Score & Pillar Breakdown
Quality Compliance
100.0
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-08-27)
Most Recent HC OutcomeCompliant · 2025-08-20
HC Attribution1 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 2 partnership announcements found in press monitoring.
Programs
— no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Partnership Signals (from press monitoring)
Company announcements, not verified evidence.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
58.0
1 manufacturing site: Indianapolis, IN
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100
Sites: Indianapolis, IN
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
StatusAvailable
1 manufacturing site: Indianapolis, IN
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100
Sites: Indianapolis, IN
Press Signals6 articles (not scored)
1 manufacturing site: Indianapolis, IN
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100
Genezen FDA Inspection History
2025-08
NAI
VAI
OAI
| Date | Site | Type | 483 citations posted | Classification |
|---|---|---|---|---|
| 2025-08-27 |
GENEZEN MA, INC.
Lexington, Massachusetts
Facility-linked
|
Human Cellular, Tissue, and Gene Therapies | Not posted | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Nov 21, 2026
Hiring Activity 26 open roles Beta
From public job postings on Genezen's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
26
open roles
24
in manufacturing, quality, PD/MSAT, engineering or regulatory (92%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 19, 2026: 1 new posting, 0 taken down.
What this may mean
- 8 of the 20 openings at Lexington, MA are in quality (QA/QC). That fits added testing or batch-release work, but it can also be normal turnover.
By function
By site
Lexington, MA
profile site
7 mfg/ops · 8 QA/QC · 3 PD/MSAT · 1 eng. · 1 other 20
7 mfg/ops · 8 QA/QC · 3 PD/MSAT · 1 eng. · 1 other 20
Indianapolis, IN
profile site
3 mfg/ops · 1 QA/QC · 1 PD/MSAT · 1 other 6
3 mfg/ops · 1 QA/QC · 1 PD/MSAT · 1 other 6
Modality words in job titles
Biologics (cell culture, USP/DSP)3
Notable roles
Director/Sr. Director, Quality Assurance Operations
Senior operations / quality role · Lexington, MA
Sr. Manager/Assoc Director, Manufacturing Sciences & Technology (MSAT)
Senior operations / quality role · Lexington, MA
Latest postings
Indirect Procurement & Strategic Sourcing Lead
Manufacturing & operations · Lexington, MA · posted Nov 19, 2026
Sr/Lead Validation Engineer
Quality (QA / QC) · Lexington, MA · posted Nov 17, 2026
Manager, Operational Excellence & Continuous Improvement
Manufacturing & operations · Lexington, MA · posted Nov 16, 2026
QA Specialist II 3:00pm-11:30pm)
Quality (QA / QC) · Lexington, MA · posted Aug 10, 2026
Lead Engineer, Manufacturing Sciences & Technology (MSAT)
Process development & MSAT · Lexington, MA · posted Nov 9, 2026
Sr. Manager/Assoc Director, Manufacturing Sciences & Technology (MSAT)
Process development & MSAT · Lexington, MA · posted Oct 30, 2026
Manager, Continuous Improvement & Human Performance
Manufacturing & operations · Lexington, MA · posted Oct 26, 2026
Director/Sr. Director, Quality Assurance Operations
Quality (QA / QC) · Lexington, MA · posted Oct 22, 2026
Manager/Senior Manager, Quality Control - Microbiology
Quality (QA / QC) · Lexington, Massachusetts · posted Oct 21, 2026
Material Handler
Manufacturing & operations · Indianapolis, Indiana · posted Oct 16, 2026
Manufacturing Technician II/III - Buffer Prep (2nd Shift, 3pm-11:30pm)
Manufacturing & operations · Lexington, MA · posted Oct 10, 2026
Scientist I, Analytical Development
Process development & MSAT · Lexington, MA · posted Sep 28, 2026
Coverage: counted from Genezen's own careers board.
Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source:
job-boards.greenhouse.io
· Checked Nov 20, 2026 · Tracking since Oct 26, 2026
Company Signals 6 articles
Company announcements, not verified evidence. They do not change any score.
Genezen and Galibra Neuroscience Partner to Advance Gene Therapy for SSADH Deficiency Toward First-in-Human Trial | Newswise - Newswise
Genezen and Galibra Neuroscience Partner to Advance Gene Therapy for SSADH Deficiency Toward First-in-Human Trial | Newswise Newswise
InterAct Taps Genezen to Advance Breast Cancer AAV8 Gene Therapy to Clinic - GenomeWeb
InterAct Taps Genezen to Advance Breast Cancer AAV8 Gene Therapy to Clinic GenomeWeb
Genezen and InterAct Therapeutics Partner to Advance AAV8-based Gene Therapy for Liver-Dominant Metastatic Breast Cancer | Newswise - Newswise
Genezen and InterAct Therapeutics Partner to Advance AAV8-based Gene Therapy for Liver-Dominant Metastatic Breast Cancer | Newswise Newswise
Genezen and InterAct Therapeutics Partner to Advance AAV8-based Gene Therapy for Liver-Dominant Metastatic Breast Cancer - PR Newswire
Genezen and InterAct Therapeutics Partner to Advance AAV8-based Gene Therapy for Liver-Dominant Metastatic Breast Cancer PR Newswire
Genezen Partners with Nevena Lešević and University of Missouri to Advance Personalized AAV9 Gene Therapy for Her Son with Ultra-Rare ARCA2 | Newswise - Newswise
Genezen Partners with Nevena Lešević and University of Missouri to Advance Personalized AAV9 Gene Therapy for Her Son with Ultra-Rare ARCA2 | Newswise Newswise
Genezen Partners with Nevena Lešević and University of Missouri to Advance Personalized AAV9 Gene Therapy for Her Son with Ultra-Rare ARCA2 - PR Newswire
Genezen Partners with Nevena Lešević and University of Missouri to Advance Personalized AAV9 Gene Therapy for Her Son with Ultra-Rare ARCA2 PR Newswire
Frequently Asked Questions About Genezen
How many FDA inspections does Genezen have on record?
CDMO Signal tracks 1 FDA inspection for Genezen, sourced from the FDA inspection database. See the full inspection history above.
Has Genezen received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Genezen.
What is Genezen's CDMO Signal Score?
Genezen has a Signal Score of 78/100, based on quality, operations, financial stability, and capacity data.
Evaluating Genezen for a manufacturing program?
Use the free AI matchmaker to compare Genezen against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Pharmaron
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 82.9
AAV, Lentiviral, Plasmid, mRNA
BioReliance (Merck)
Glasgow, UK · Rockville, MD
Signal Score: 80.3
AAV, Lentiviral, Biologics
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 79.9
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
Compare Genezen with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.